Close

Baxter Announces Appointment of Interim President for Its Renal Business

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

Baxter International Inc. announced that Jill Schaaf, who served as President, Renal, since May 2014, will be leaving the company. Effective May 3, 2016, Giuseppe Accogli, former region head for Baxter’s U.S. Renal business, has assumed the role of Interim President, Renal, while the company completes its search to permanently fill the role.

World pharma today/-news/-Baxter Chairman and CEO José (Joe) Almeida said that we would like to express our gratitude to Jill for her 15 years of service to Baxter, Throughout her career at Baxter, Jill has been dedicated to improving the lives of our renal patients worldwide.

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

 

Latest stories